Skip to main content

May 2014 Vol 7, No 3

The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy- Induced Nausea and Vomiting: Systematic Review of the Literature

Michael S. Broder, MD, MSHS, Claudio Faria, PharmD, MPH, Annette Powers, PharmD, MBA, Jehangeer Sunderji, MD, Dasha Cherepanov, PhD

Stakeholder Perspective

The Value of Pharmaceuticals in the Prevention and Treatment of CINV

by Atheer A. Kaddis, PharmD

Cancer Care in 2014: Continuing Challenges, New Opportunities

Dalia Buffery, MA, ABD

Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population

Saurabh Ray, PhD, Machaon M. K. Bonafede, PhD, MPH, Nimish A. Mohile, MD, Jeffrey A. Bourret, PharmD

Stakeholder Perspective

Treatment Decisions in the Management of Malignant Gliomas

Payers’ Management of Oncology Drugs: Opportunities and Challenges

James T. Kenney, RPh, MBA

Where Is the Fix?

David B. Nash, MD, MBA

Current Challenges in Health Economic Modeling of Cancer Therapies: A Research Inquiry

Jeffrey D. Miller, MS, Kathleen A. Foley, PhD, Mason W. Russell, MAPE

Stakeholder Perspective

Disruptive Innovation, Uncertain Value, and Economic Modeling in Oncology

by Michael F. Murphy, MD, PhD

Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study

Kirk J. Wojno, MD, Frank J. Costa, MD, Robert J. Cornell, MD, Jeffrey D. Small, MD, Erik Pasin, MD, Wim Van Criekinge, PhD, Joseph W. Bigley, MSc, Leander Van Neste, PhD

Stakeholder Perspective

Molecular Tests Can Help to Reduce Repeated Prostate Biopsies

by Kelly Huang, PhD

Results 1 - 7 of 7